Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman
StockNews.AI • 2 days
High Materiality10/10
Information
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The latest adverse development for Corcept Therapeu...
Original sourceAI Summary
Corcept Therapeutics faced adverse developments after the FDA warned against relacorilant's submission, resulting in a 17% stock drop. The ongoing investigation by Hagens Berman could further impact investor sentiment and confidence in the company's future prospects.
Sentiment Rationale
Regulatory setbacks and investor discontent following FDA communications can significantly depress CORT's share price. Historical cases of similar FDA rejections have led to prolonged stock declines.
Trading Thesis
CORT shares are likely to remain under pressure in the short term due to regulatory setbacks.
Market-Moving
- FDA's warning against relacorilant submission significantly impacts investor confidence.
- Upcoming investor lawsuits could elicit further market reactions.
- Any new FDA communications could lead to additional stock volatility.
- Potential revisions to relacorilant’s filing or data could alter market sentiment.
Key Facts
- Corcept's relacorilant faces FDA rejection, shares drop 17%.
- FDA warned Corcept multiple times against submitting drug application.
- Hagens Berman investigating potential investor misrepresentation by Corcept.
- Market cap decreased by $3.2 billion since December 2025.
- Investors lost confidence due to CRL and FDA safety concerns.
Companies Mentioned
- Corcept Therapeutics (CORT): Facing regulatory hurdles and investor lawsuits, significantly impacting stock value.
- Hagens Berman (N/A): Leading the investigation into potential misrepresentation, affecting public perception of CORT.
Corporate Developments
This news falls under 'Corporate Developments' as it centers on critical regulatory issues that may dictate the company's future. The ongoing investigation adds to the uncertainty surrounding CORT's market performance.